Differentiating members of the thiazolidinedione class: a focus on efficacy (Q34580989)

3 August 2017

1 reference

title

Differentiating members of the thiazolidinedione class: a focus on efficacy (English)

1 reference

3 August 2017

Barry J Goldstein

1

1 reference

3 August 2017

1 March 2002

1 reference

Diabetes - Metabolism: Research and Reviews

3 August 2017

1 reference

3 August 2017

18 Suppl 2

1 reference

3 August 2017

S16-22

1 reference

Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats

3 August 2017

1 reference

The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat.

21 January 2018

1 reference

Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5-[4-(1-Methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), a New Antidiabetic Agent

21 January 2018

1 reference

Rates of hypoglycemia in users of sulfonylureas.

21 January 2018

1 reference

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

21 January 2018

1 reference

The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats.

21 January 2018

1 reference

Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators

21 January 2018

1 reference

Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone

21 January 2018

1 reference

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

21 January 2018

1 reference

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.

21 January 2018

1 reference

Induction of insulin resistance by glucosamine reduces blood flow but not interstitial levels of either glucose or insulin.

21 January 2018

1 reference

Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group.

21 January 2018

1 reference

Trp64Arg mutation of beta3-adrenoceptor gene deteriorates lipolysis induced by beta3-adrenoceptor agonist in human omental adipocytes.

21 January 2018

1 reference

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

21 January 2018

1 reference

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

21 January 2018

1 reference

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

21 January 2018

1 reference

Surgical removal of visceral fat reverses hepatic insulin resistance.

21 January 2018

1 reference

Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

21 January 2018

1 reference

Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.

21 January 2018

1 reference

Inheritance of a mitochondrial DNA defect and impaired glucose tolerance in BHE/Cdb rats

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Hepatic dysfunction associated with troglitazone

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/DMRR.251

1 reference

3 August 2017

1 reference

PubMed ID

11921434